{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:03:53Z","timestamp":1792598633690,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.nmd.2025.106208","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T15:02:49Z","timestamp":1755961369000},"page":"106208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"54","author":[{"given":"Jodi M.","family":"Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Capocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evrim","family":"Atas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana X.","family":"Bharucha-Goebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Brandsema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai K.","family":"ElMallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"Goedeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Goude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Hesterlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Matesanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mercado-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deipanjan","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Proud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Ramos-Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Salabarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Camino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Shell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Soslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane B.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravindhan","family":"Veerapandiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chet","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele L.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"Zaidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Leon-Astudillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-1756","authenticated-orcid":false,"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2025.106208_bib0001","unstructured":"FDA approves first gene therapy for treatment of certain patients with duchenne muscular dystrophy. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy."},{"issue":"7","key":"10.1016\/j.nmd.2025.106208_bib0002","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.nmd.2025.106208_bib0003","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of In vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther."},{"key":"10.1016\/j.nmd.2025.106208_bib0004","series-title":"MDA clinical & scientific conference","article-title":"Two-year safety and exploratory efficacy of AT845 gene replacement therapy for late onset Pompe disease: FORTIS, a phase 1\/2 open-label clinical study","author":"Mozaffar","year":"2024"},{"issue":"2","key":"10.1016\/j.nmd.2025.106208_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020302","article-title":"Gene therapy developments for pompe disease","volume":"10","author":"Unnisa","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.nmd.2025.106208_bib0006","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/WCO.0000000000001187","article-title":"Current avenues of gene therapy in Pompe disease","volume":"36","author":"Leon-Astudillo","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2025.106208_bib0007","doi-asserted-by":"crossref","unstructured":"Ma X., Li J., Wang X., Ma W., Wang J., Gu R., et al. First-in-human case report: AAV9-hGAA gene therapy for a patient with infantile-onset Pompe disease. MedRxiv. 2022 Dec 26. doi:10.1101\/2022.12.22.22283398.","DOI":"10.1101\/2022.12.22.22283398"},{"issue":"12","key":"10.1016\/j.nmd.2025.106208_bib0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2025.106208_bib0009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41591-023-02730-9","article-title":"Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E\/R4: phase 1\/2 trial results","volume":"30","author":"Mendell","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.nmd.2025.106208_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021130","article-title":"Gene therapy in ALS and SMA: advances, challenges and perspectives","volume":"24","author":"Lejman","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.nmd.2025.106208_bib0011","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213604","article-title":"Delandistrogene moxeparvovec gene therapy in individuals with duchenne muscular dystrophy: evidence in focus: report of the AAN guidelines subcommittee","volume":"104","author":"Oskoui","year":"2025","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.nmd.2025.106208_bib0012","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213776","article-title":"Microdystrophin gene therapy for duchenne muscular dystrophy","volume":"104","author":"Smith","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2025.106208_bib0013","unstructured":"Marks P. FDA Center Director Decisional Memo - ELEVIDYS. Available from: https:\/\/www.fda.gov\/media\/169707\/download."},{"key":"10.1016\/j.nmd.2025.106208_bib0014","unstructured":"Administration USFaD. ELEVIDYS. https:\/\/www.fda.gov\/vaccines-blood-biologics\/tissue-tissue-products\/elevidys."},{"key":"10.1016\/j.nmd.2025.106208_bib0015","unstructured":"Teenager who received Elevidys, Sarepta\u2019s Duchenne gene therapy, dies. 2025. https:\/\/www.statnews.com\/2025\/03\/18\/elevidys-sarepta-duchenne-death\/."},{"issue":"3","key":"10.1016\/j.nmd.2025.106208_bib0016","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.nmd.2025.106208_bib0017","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy","volume":"47","author":"Galletta","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"10.1016\/j.nmd.2025.106208_bib0018","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.ymthe.2022.11.007","article-title":"Secondary hemophagocytic lymphohistiocytosis following Zolgensma therapy: an evolving story on the innate response to systemic gene therapy","volume":"30","author":"Byrne","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2025.106208_bib0019","series-title":"Systemic AAV delivery activates the classical complement pathway leading to thrombotic microangiopathy","author":"Salabarria","year":"2021"},{"issue":"1","key":"10.1016\/j.nmd.2025.106208_bib0020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.nmd.2025.106208_bib0021","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.nmd.2025.106208_bib0022","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1007\/s00415-024-12431-z","article-title":"Immune-mediated myositis following gene therapy for Duchenne muscular dystrophy: a case report","volume":"271","author":"Iannaccone","year":"2024","journal-title":"J Neurol"},{"issue":"24","key":"10.1016\/j.nmd.2025.106208_bib0023","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nmd.2025.106208_bib0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/22143602241303357","article-title":"Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; consensus recommendations for cardiac surveillance","volume":"12","author":"Kaufman","year":"2025","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2025.106208_bib0025","doi-asserted-by":"crossref","unstructured":"Potter R.A., Moeller I.H., Khan S., Haegel H., Hollenstein A., Steiner G., et al. Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy. Sci Rep. 2025 Jan 2;15(1):4. doi:10.1038\/s41598-024-84077-w.","DOI":"10.1038\/s41598-024-84077-w"},{"key":"10.1016\/j.nmd.2025.106208_bib0026","unstructured":"ELEVIDYS (delandistrogene moxeparvovec-rokl) package insert. 2023. https:\/\/www.fda.gov\/media\/169679\/download."},{"issue":"4","key":"10.1016\/j.nmd.2025.106208_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10040241","article-title":"Genotype-phenotype correlations in Duchenne and Becker muscular dystrophy patients from the Canadian neuromuscular disease registry","volume":"10","author":"Lim","year":"2020","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.nmd.2025.106208_bib0028","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec gene therapy in ambulatory patients (Aged \u22654 to <8\u2009Years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2025.106208_bib0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2025.106208_bib0030","unstructured":"FDA expands approval of gene therapy for patients with Duchenne muscular dystrophy. 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy#:~:text=Data%20Supporting%20Accelerated%20Approval,in%20the%20non%2Dambulatory%20population."},{"key":"10.1016\/j.nmd.2025.106208_bib0031","unstructured":"Sarepta Therapeutics provides update on ELEVIDYS. 2025. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-provides-update-elevidys."},{"issue":"4","key":"10.1016\/j.nmd.2025.106208_bib0032","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.nmd.2025.106208_bib0033","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat Med"},{"issue":"7\u20138","key":"10.1016\/j.nmd.2025.106208_bib0034","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/01926233231201408","article-title":"An overview of nonclinical and clinical liver toxicity associated with AAV gene therapy","volume":"51","author":"Whiteley","year":"2023","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.nmd.2025.106208_bib0035","doi-asserted-by":"crossref","unstructured":"Ertl H.C.J. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022 Aug 12;13:975803. doi:10.3389\/fimmu.2022.975803.","DOI":"10.3389\/fimmu.2022.975803"},{"issue":"Suppl 1","key":"10.1016\/j.nmd.2025.106208_bib0036","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jvh.13919","article-title":"Hepatitis after gene therapy, what are the possible causes?","volume":"31","author":"Maina","year":"2024","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.nmd.2025.106208_bib0037","unstructured":"B\u00f6nnemann C. AAV gene therapy related immune responses: selected clinical observations from the GAN, DMD, and MTM1 trials. FDA & ASGCT\u2019s Immune responses to AAV vectors; 2023 Jan 27. https:\/\/www.asgct.org\/publications\/news\/january-2023\/fda-immune-responses-to-aav-vectors-event."},{"key":"10.1016\/j.nmd.2025.106208_bib0038","unstructured":"Assessment of cardiac outcomes in DelandistrogeneMoxeparvovec clinical trials for Duchenne muscular dystrophy. 2025. https:\/\/investorrelations.sarepta.com\/static-files\/383feb10-2a3a-42ef-b5ce-f3062e7c65c2."},{"issue":"7","key":"10.1016\/j.nmd.2025.106208_bib0039","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.amjcard.2015.01.030","article-title":"Dystrophin genotype-cardiac phenotype correlations in Duchenne and Becker muscular dystrophies using cardiac magnetic resonance imaging","volume":"115","author":"Tandon","year":"2015","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.nmd.2025.106208_bib0040","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00246-021-02807-7","article-title":"Current practices in treating cardiomyopathy and heart failure in duchenne muscular dystrophy (DMD): understanding care practices in order to optimize DMD heart failure through ACTION","volume":"43","author":"Villa","year":"2022","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"10.1016\/j.nmd.2025.106208_bib0041","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12872-022-02688-5","article-title":"Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging","volume":"22","author":"Batra","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"10.1016\/j.nmd.2025.106208_bib0042","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2025.106208_bib0043","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","article-title":"Givinostat: an emerging treatment for polycythemia vera","volume":"29","author":"Chifotides","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.nmd.2025.106208_bib0044","unstructured":"DUVYZAT (givinostat) insert. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217865Orig1s000lbl.pdf."},{"key":"10.1016\/j.nmd.2025.106208_bib0045","unstructured":"Design and analysis of shedding studies for virus or bacteria-based gene therapy and oncolytic products. 2015. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products."},{"key":"10.1016\/j.nmd.2025.106208_bib0046","series-title":"26th annual meeting of the American Society of Gene + Cell Therapy","article-title":"Vector shedding in patients with DMD treated withdelandistrogene moxeparvovec and seroconversionfrom shed vector in na\u00efve mice","author":"Smith","year":"2023"},{"issue":"3","key":"10.1016\/j.nmd.2025.106208_bib0047","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.nmd.2025.106208_bib0048","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf"},{"issue":"15\u201316","key":"10.1016\/j.nmd.2025.106208_bib0049","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re: \u201cmoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by wilson and flotte","volume":"31","author":"Shieh","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.nmd.2025.106208_bib0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting report: 2022 muscular dystrophy association summit on \u201csafety and challenges in gene transfer therapy\u201d","volume":"10","author":"Lek","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2025.106208_bib0051","doi-asserted-by":"crossref","unstructured":"Guillou J., de Pellegars A., Porcheret F., Fr\u00e9meaux-Bacchi V., Allain-Launay E., Debord C., et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 2022 Jul 26;6(14):4266\u201370. doi:10.1182\/bloodadvances.2021006419.","DOI":"10.1182\/bloodadvances.2021006419"},{"key":"10.1016\/j.nmd.2025.106208_bib0052","unstructured":"Patient with DMD dies in Pfizer\u2019s phase 2 gene therapy trial [Internet]. 2024. https:\/\/www.cgtlive.com\/view\/patient-dmd-dies-pfizer-phase-2-gene-therapy-trial."},{"issue":"8","key":"10.1016\/j.nmd.2025.106208_bib0053","first-page":"2223","article-title":"Special considerations in interpreting liver function tests","volume":"59","author":"Johnston","year":"1999","journal-title":"Am Fam Phys"},{"key":"10.1016\/j.nmd.2025.106208_bib0054","article-title":"Management of acute liver toxicity after delandistrogene-moxeparvovec with the use of steroid sparing agents","author":"Leon-Astudillo","year":"2025","journal-title":"MDA Conf"},{"key":"10.1016\/j.nmd.2025.106208_bib0055","unstructured":"Community letter: ELEVIDYS safety update. 2025. https:\/\/www.sarepta.com\/community-letter-elevidys-safety-update."}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625009356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625009356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T03:04:46Z","timestamp":1763521486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625009356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":55,"alternative-id":["S0960896625009356"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106208","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106208"}}